Pioneering biomarker technologies for Cancer therapies

Our biomarkers are used to identify the right patient, the right drug and the right dose.

Biomarker Tests


Using our biomarker tests provides more effective treatment for patients and economic savings for the healthcare system. Our colorectal cancer tests are validated using thousands of patient samples and are set to transform the current treatment pathway.

We have reached a crossroads in cancer treatment, where we can apply innovative tests on the patient’s blood and tumour tissue to select which patients need chemotherapy, what drugs will be most effective and what is a safe dose, reducing the risk of side effects. Our portfolio of biomarker tests allows us to make a step change in the treatment of early stage colorectal cancer, a disease affecting 1.2 million new patients every year, presenting a major global burden of morbidity and mortality.”

Prof. David Kerr CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci.

March 7, 2018

MBM and OCB launch ColoProg in China on March 7th 2018

Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cancer patients to be available throughout China Oxford UK, and Shanghai China March 7th 2018 The launch of ColoProg represents a first for precision oncology in Greater China, signifying the ongoing success of the collaboration between Ningbo My-BioMed Biotechnology Co. Ltd (MBM) and Oxford Cancer... more

October 9, 2017

Oxford Cancer Biomarkers appoints David Browning as its Chief Executive Officer and Board member

Oxford, UK, 9th October 2017 Oxford Cancer Biomarkers has appointed healthcare industry leader David Browning as Chief Executive Officer and member of the Board. This represents an important milestone for the company which aims to benefit cancer patients through the implementation of advanced precision oncology diagnostics to improve screening and enable better treatment decisions for people... more

September 4, 2017

MBM and OCB announce the set-up of joint laboratories in Ningbo Meishan and Oxford at the 3rd China Medical Devices Int’l Summit on 26th August 2017

Oxford, UK, 1st September 2017 The announcement, at the 3rd China Medical Devices Int’l Summit, follows the signing in March 2017 of a memorandum of strategic collaboration between Oxford Cancer Biomarkers (OCB) and Ningbo My-BioMed Biotechnology Co. Ltd (MBM). MBM and OCB announced as part of ‘the Belt and Road Medical Cooperation Initiative’ that both parties will establish joint... more